Literature DB >> 20580029

Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status.

Stefania Lamon-Fava1, David M Herrington, Katalin V Horvath, Ernst J Schaefer, Bela F Asztalos.   

Abstract

Type 2 diabetes mellitus is associated with dyslipidemia and with an increased risk of coronary heart disease (CHD). Our objective was to compare the effects of hormone replacement therapy (HRT) on plasma lipoproteins and coronary disease progression in postmenopausal women with and without diabetes. Study subjects were participants in the Estrogen Replacement and Atherosclerosis trial, a placebo-controlled, randomized trial of HRT (conjugated equine estrogen 0.625 mg/d with or without medroxyprogesterone acetate 2.5 mg/d) in postmenopausal women with established CHD (mean age, 65 ± 7 years). Plasma remnant lipoprotein levels and high-density lipoprotein (HDL) subpopulation levels were measured at baseline and year 1. Quantitative coronary angiography was assessed at baseline and at follow-up. At baseline, remnant lipoprotein levels were significantly higher and HDL cholesterol (HDL-C) levels were significantly lower in diabetic women than in women without diabetes. Hormone replacement therapy lowered remnant lipoproteins and increased HDL-C and large HDL particle levels in both groups. However, during HRT, levels of these parameters were still significantly worse in diabetic women than in nondiabetic women. A significant interaction between HRT and diabetes status, with greater increases in plasma atheroprotective HDL α1 particles in nondiabetic women than in diabetic women during HRT, was observed. Coronary heart disease progressed significantly more in women with diabetes than in women without diabetes. Our findings indicate that diabetes attenuates the HRT-related increase in atheroprotective HDL α1 particles. Faster progression of coronary atherosclerosis in women with diabetes could be mediated in part by a worse lipoprotein profile in these women than in women without diabetes, both before and during HRT.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580029      PMCID: PMC2947588          DOI: 10.1016/j.metabol.2010.05.012

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  40 in total

1.  Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes.

Authors:  K E Friday; C Dong; R U Fontenot
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

2.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

3.  The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort.

Authors:  D M Herrington; D M Reboussin; K P Klein; P C Sharp; S A Shumaker; T E Snyder; K R Geisinger
Journal:  Control Clin Trials       Date:  2000-06

4.  Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study.

Authors:  Ernst J Schaefer; Judith R McNamara; Paulesh K Shah; Katsuyuki Nakajima; L Adrienne Cupples; Jose M Ordovas; Peter W F Wilson
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

5.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

6.  Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease.

Authors:  Oliviero Olivieri; Antonella Bassi; Chiara Stranieri; Elisabetta Trabetti; Nicola Martinelli; Francesca Pizzolo; Domenico Girelli; Simonetta Friso; Pier Franco Pignatti; Roberto Corrocher
Journal:  J Lipid Res       Date:  2003-10-16       Impact factor: 5.922

7.  Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.

Authors:  Barbara V Howard; Judith Hsia; Pamela Ouyang; Lucy Van Voorhees; Joseph Lindsay; Angela Silverman; Edwin L Alderman; Mark Tripputi; David D Waters
Journal:  Circulation       Date:  2004-06-28       Impact factor: 29.690

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.

Authors:  Bela F Asztalos; Marcelo Batista; Katalin V Horvath; Caitlin E Cox; Gerard E Dallal; Josh S Morse; Greg B Brown; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-13       Impact factor: 8.311

10.  Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women.

Authors:  Stefania Lamon-Fava; David M Herrington; David M Reboussin; Michelle Sherman; Katalin Horvath; Ernst J Schaefer; Bela F Asztalos
Journal:  Atherosclerosis       Date:  2008-12-24       Impact factor: 5.162

View more
  6 in total

1.  Lipoprotein remodeling generates lipid-poor apolipoprotein A-I particles in human interstitial fluid.

Authors:  Norman E Miller; Waldemar L Olszewski; Hiroaki Hattori; Irina P Miller; Takeshi Kujiraoka; Tomoichiro Oka; Tadao Iwasaki; M Nazeem Nanjee
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-11       Impact factor: 4.310

Review 2.  The Regulation of Adipose Tissue Health by Estrogens.

Authors:  Benjamin M Steiner; Daniel C Berry
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

3.  Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors.

Authors:  Tomas Vaisar; Jennifer L Gordon; Jake Wimberger; Jay W Heinecke; Alan L Hinderliter; David R Rubinow; Susan S Girdler; Katya B Rubinow
Journal:  J Clin Lipidol       Date:  2020-11-24       Impact factor: 4.766

4.  Metabolic syndrome in premenopausal and postmenopausal women with type 2 diabetes: loss of protective effects of premenopausal status.

Authors:  Manouchehr Nakhjavani; Mehrnaz Imani; Mehrdad Larry; Arash Aghajani-Nargesi; Afsaneh Morteza; Alireza Esteghamati
Journal:  J Diabetes Metab Disord       Date:  2014-11-23

Review 5.  Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?

Authors:  Marília Izar Helfenstein Fonseca; Isis Tande da Silva; Sandra Roberta G Ferreira
Journal:  Diabetol Metab Syndr       Date:  2017-04-07       Impact factor: 3.320

6.  The gut microbiota during the progression of atherosclerosis in the perimenopausal period shows specific compositional changes and significant correlations with circulating lipid metabolites.

Authors:  Qinghai Meng; Menghua Ma; Weiwei Zhang; Yunhui Bi; Peng Cheng; Xichao Yu; Yu Fu; Ying Chao; Tingting Ji; Jun Li; Qi Chen; Qichun Zhang; Yu Li; Jinjun Shan; Huimin Bian
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.